Cervical cancer screening for individuals at average risk
American Cancer Society

Ca-A Cancer Journal for Clinicians

70, 321-346

DOI: 10.3322/caac.21628

Citation Report

#	Article	IF	Citations
1	Screening for Cervical Cancer. Medical Clinics of North America, 2020, 104, 1063-1078.	1.1	25
2	Clinical needs for transgender men in the gynecologic oncology setting. Gynecologic Oncology, 2020, 159, 899-905.	0.6	20
3	Cervical Cancer Screening Guidelines in the Postvaccination Era: Review of the Literature. Journal of Oncology, 2020, 2020, 1-14.	0.6	22
4	Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?. Journal of the American Society of Cytopathology, 2020, 9, 602-606.	0.2	8
5	Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 474-484.	1.1	24
6	Five-year retrospective review in gynecologic cytopathology: is it time to amend?. Journal of the American Society of Cytopathology, 2021, 10, 141-147.	0.2	0
7	Elimination of cervical cancer in U.S. Hispanic populations: Puerto Rico as a case study. Preventive Medicine, 2021, 144, 106336.	1.6	13
8	TruScreen detection of cervical tissues for high-risk human papillomavirus-infected women during the COVID-19 pandemic. Future Oncology, 2021, 17, 1197-1207.	1.1	6
9	Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 72, 1529-1537.	2.9	8
10	Summary of Current Guidelines for Cervical Cancer Screening and Management of Abnormal Test Results: 2016â€“2020. Journal of Women's Health, 2021, 30, 5-13.	1.5	31
11	The performance of Cobas HPV test for cervical cancer screening in Chinese female migrant workers. Epidemiology and Infection, 2021, 149, e196.	1.0	1
12	Cancer Statistics, 2021. Ca-A Cancer Journal for Clinicians, 2021, 71, 7-33.	157.7	12,002
13	Clinicopathological Characteristics of Microscopic Tubal Intraepithelial Metastases from Adenocarcinoma and Small Cell Neuroendocrine Carcinoma of the Uterine Cervix. In Vivo, 2021, 35, 2469-2481.	0.6	6
14	Cervical Screening Performance. American Journal of Clinical Pathology, 2021, 155, 616-620.	0.4	3
15	Analysis of the results of national screening programs for early active diagnosis of cervical cancer and proposal of improvement strategy. Ginecologia Ro, 2021, 3, 30.	0.0	1
16	Lymphoma of the uterine cervix- a rare clinical presentation: A case report. Vojnosanitetski Pregled, 2022, 79, 1262-1266.	0.1	0
17	The Pap smear test value in dysplasia and cervical cancer diagnosis. Obstetrica Si Ginecologie, 2021, 1, 6.	0.0	0
18	NEAT1 as a competing endogenous RNA in tumorigenesis of various cancers: Role, mechanism and therapeutic potential. International Journal of Biological Sciences, 2021, 17, 3428-3440.	2.6	45

#	Article	IF	Citations
19	Cervical cancer screening: Should my practice switch to primary HPV testing?. , 2021, 33, .		0
20	Prevalence of highâ€risk human papillomavirus genotypes in two regions of Peru. International Journal of Gynecology and Obstetrics, 2021, 154, 544-549.	1.0	0
21	A Pilot Study of Human Papillomavirus Detection in Urine Using a Novel Nucleic Acid Amplification Test. journal of applied laboratory medicine, The, 2021, 6, 474-479.	0.6	3
22	Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca-A Cancer Journal for Clinicians, 2021, 71, 209-249.	157.7	52,977
23	Changes in Test Volumes During Coronavirus Disease 2019 (COVID-19): A Laboratory Stewardship Opportunity. Archives of Pathology and Laboratory Medicine, 2021, 145, 821-824.	1.2	7
24	HPV infection - Screening, diagnosis and management of HPV-induced lesions. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 240-246.	0.3	0
25	Cervical Cancer Screeningâ€"Past, Present, and Future. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 432-434.	1.1	8
26	Evaluation of the Onclarity HPV assay on the high-throughput COR system. Expert Review of Molecular Diagnostics, 2021, 21, 333-342.	1.5	6
27	Risk-based cervical screening guidelines should utilize large diverse national database and specifically measure invasive cancer risk of screened patients. Gynecology and Obstetrics Clinical Medicine, 2021, 1, 2-4.	0.2	0
28	State of the Science: Screening, Surveillance, and Epidemiology of HPV-Related Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 377-388.	1.8	9
29	The Development of Human Papillomavirus (HPV) Vaccines and Current Barriers to Implementation. Immunological Investigations, 2021, 50, 821-832.	1.0	5
30	Updated American Cancer Society HPV vaccine guideline seeks to reinforce key messages. Cancer, 2021, 127, 1169-1170.	2.0	0
31	New Trends of Cervical Cancer Incidence in Kazakhstan. Asian Pacific Journal of Cancer Prevention, 2021, 22, 1295-1304.	0.5	5
32	Urine HPV in the Context of Genital and Cervical Cancer Screeningâ€"An Update of Current Literature. Cancers, 2021, 13, 1640.	1.7	27
33	Cervical screening during the COVID-19 pandemic: optimising recovery strategies. Lancet Public Health, The, 2021, 6, e522-e527.	4.7	37
34	Split-type electrochemiluminescent gene assay platform based on gold nanocluster probe for human papillomavirus diagnosis. Biosensors and Bioelectronics, 2021, 178, 113044.	5.3	19
35	Evaluation of amide proton transfer-weighted imaging for endometrial carcinoma histological features: a comparative study with diffusion kurtosis imaging. European Radiology, 2021, 31, 8388-8398.	2.3	11
36	American Cancer Society signals transition in cervical cancer screening from cytology to HPV tests. Cancer Cytopathology, 2021, 129, 259-261.	1.4	1

#	Article	IF	Citations
37	Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014. JAMA Network Open, 2021, 4, e218373.	2.8	15
38	Effects of Message Framing on Cervical Cancer Screening Knowledge and Intentions Related to Primary HPV Testing. Cancer Prevention Research, 2021, 14, 839-844.	0.7	3
39	The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell, 2021, 184, 1661-1670.	13.5	113
40	Genderâ€neutral HPV elimination, cervical cancer screening, and treatment: Experience from Bhutan. International Journal of Gynecology and Obstetrics, 2022, 156, 425-429.	1.0	10
41	Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States in 2018 and 2019, with a Focus on Smoking Cessation. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1287-1299.	1.1	34
42	Frequency of high-grade squamous cervical lesions among women over age 65 years living with HIV. American Journal of Obstetrics and Gynecology, 2021, 225, 411.e1-411.e7.	0.7	0
43	Deciphering Pap Guidelines and Determining Management in Primary Care. Advances in Family Practice Nursing, 2021, 3, 95-109.	0.1	0
44	Participatory innovation for human papillomavirus screening to accelerate the elimination of cervical cancer. The Lancet Global Health, 2021, 9, e582-e583.	2.9	12
45	The other side of screening: predictors of treatment and follow-up for anal precancers in a large health system. Aids, 2021, 35, 2157-2162.	1.0	11
46	The ASCCP Cervical Cancer Screening Task Force Endorsement and Opinion on the American Cancer Society Updated Cervical Cancer Screening Guidelines. Journal of Lower Genital Tract Disease, 2021, 25, 187-191.	0.9	30
48	The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features. Journal of Clinical Epidemiology, 2021, 139, 319-329.	2.4	5
49	Genetic and Epigenetic Variations of HPV52 in Cervical Precancer. International Journal of Molecular Sciences, 2021, 22, 6463.	1.8	9
50	Human Papilloma Virus Vaccination. Viruses, 2021, 13, 1091.	1.5	31
51	Do we need the word â€˜womanâ€™ in healthcare?. Postgraduate Medical Journal, 2021, 97, 483-484.	0.9	12
52	Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3. Gynecologic Oncology, 2021, 161, 741-747.	0.6	16
53	It's time to re-evaluate cervical Cancer screening after age 65. Gynecologic Oncology, 2021, 162, 200-202.	0.6	14
54	Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study. BMC Medicine, 2021, 19, 164.	2.3	26
55	Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States. American Journal of Obstetrics and Gynecology, 2021, 225, 649.e1-649.e9.	0.7	2

#	Article	IF	Citations
56	Eliminating Cervical Cancer: Progress and Challenges for High-income Countries. Clinical Oncology, 2021, 33, 550-559.	0.6	32
57	Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports, 2021, 70, 1-187.	26.7	841
58	Factors Influence on Pap Test Screening among Lahu Hill Tribe Women in Remote Area Thailand. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2243-2249.	0.5	2
59	HPV Screening Test for the Detection of Precancerous Cervical Lesions and Cervical Cancer in Israeli Women. Acta Cytologica, 2021, 65, 1-7.	0.7	2
60	Natural history of histologically confirmed high-grade cervical intraepithelial neoplasia during pregnancy: meta-analysis. BMJ Open, 2021, 11, e048055.	0.8	1
61	Yes! To Scaling Up Cervical Cancer Screening With Self-Collection: But the Cost of HPV Screening Must Be Reduced. JCO Global Oncology, 2021, 7, 1327-1328.	0.8	0
62	Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15â€“64 years in Botswana. PLoS ONE, 2021, 16, e0255581.	1.1	9
63	Symptomatic presentation of cervical cancer in emergency departments in California. Cancer Causes and Control, 2021, 32, 1411-1421.	0.8	0
64	Cervical Cancer Screening in South Florida Veteran Population, 2014 to 2020: Cytology and High-Risk Human Papillomavirus Correlation and Epidemiology. Cureus, 2021, 13, e17247.	0.2	1
66	Genistein: Dual Role in Womenâ€™s Health. Nutrients, 2021, 13, 3048.	1.7	26
67	Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort. Gynecologic Oncology, 2021, 162, 308-314.	0.6	11
68	Cancer statistics for the US Hispanic/Latino population, 2021. Ca-A Cancer Journal for Clinicians, 2021, 71, 466-487.	157.7	176
69	Increased Nuclear Transporter Importin 7 Contributes to the Tumor Growth and Correlates With CD8 T Cell Infiltration in Cervical Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 732786.	1.8	9
70	Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013â€“2019. Gynecologic Oncology, 2021, 163, 378-384.	0.6	14
71	Cervical cancer prevention and control in women living with human immunodeficiency virus. Ca-A Cancer Journal for Clinicians, 2021, 71, 505-526.	157.7	70
72	Cervical cancer screening guidelines. JAAPA: Official Journal of the American Academy of Physician Assistants, 2021, 34, 21-24.	0.1	3
73	Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. American Journal of Obstetrics and Gynecology, 2022, 226, 228.e1-228.e9.	0.7	8
74	Increasing Cervical Cancer Prevention Through HPV Testing: Challenges in Developing Persuasive Messages. Cancer Prevention Research, 2021, 14, 823-824.	0.7	0

#	Article	IF	Citations
75	The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase. American Journal of Obstetrics and Gynecology, 2021, 225, 278.e1-278.e16.	0.7	12
76	Ruralâ€urban differences in HPV testing for cervical cancer screening. Journal of Rural Health, 2022, 38, 409-415.	1.6	9
77	Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States. Gynecologic Oncology, 2021, 162, 555-559.	0.6	11
78	Molecular markers for cervical cancer screening. Expert Review of Proteomics, 2021, 18, 675-691.	1.3	21
79	De-implementation of cervical cancer screening before age 21. Preventive Medicine, 2021, 153, 106815.	1.6	1
80	Invasive Cervical Cancer After a Positive Pap Test Result and Negative Human Papillomavirus Test Result. Obstetrics and Gynecology, 2021, Publish Ahead of Print, 580-581.	1.2	0
81	Precision Prevention: The 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Molecular Pathology, 2021, 2, 274-280.	0.5	1
82	Risk Assessment of Human Papillomavirusâ€"Positive Cytology-Negative Cervical Cancer Screening in Black and White Women. American Journal of Clinical Pathology, 2021, , .	0.4	0
83	Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis. Preventive Medicine, 2021, 151, 106623.	1.6	34
84	Cancer Equity and Affirming Care: An Overview of Disparities and Practical Approaches for the Care of Transgender, Gender-Nonconforming, and Nonbinary People. Clinical Journal of Oncology Nursing, 2021, 25, 25-35.	0.3	2
85	Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies. Seminars in Radiation Oncology, 2021, 31, 309-323.	1.0	0
86	Prevalence of Positive Cervical Cancer Screening Tests Past the Age of 65 Years With Prior Adequate Negative Screening. Journal of Lower Genital Tract Disease, 2021, 25, 263-266.	0.9	1
87	Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond. Preventive Medicine, 2021, 151, 106595.	1.6	23
88	Impact of COVID-19 on cervical cancer screening: Challenges and opportunities to improving resilience and reduce disparities. Preventive Medicine, 2021, 151, 106596.	1.6	68
89	Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media. Tumour Virus Research, 2021, 12, 200224.	1.5	1
90	History, physical examination, and preventive health care. , 2022, , 127-139.e2.		0
91	Comparison between Urine and Cervical High-Risk HPV Tests for Japanese Women with ASC-US. Diagnostics, 2021, 11, 1895.	1.3	0
92	Cervical cancer prevention becomes more efficient. International Journal of Cancer, 2022, 150, 395-396.	2.3	0

#	Article	IF	Citations
93	Patient-Centered Home Cancer Screening Attitudes During COVID-19 Pandemic. Journal of Patient-centered Research and Reviews, 2021, 8, 340-346.	0.6	7
94	Flexible Magnifying Endoscopy with Narrow Band Imaging for Diagnosing Uterine Cervical Neoplasms: A Multicenter Prospective Study. Journal of Clinical Medicine, 2021, 10, 4753.	1.0	2
95	Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Applied Biochemistry and Biotechnology, 2022, 194, 570-586.	1.4	10
96	Is Primary HPV with Secondary p16/Ki67 Dual-Stain an Alternative HSIL-Risk Detection Strategy in Cervical Cancer Screening for Women under 30 Years?. Diagnostics, 2021, 11, 2012.	1.3	10
97	Chlamydia and HPV induce centrosome amplification in the host cell through additive mechanisms. Cellular Microbiology, 2021, 23, e13397.	1.1	6
98	The Current and Future States of Screening in Gynecologic Cancers. Obstetrics and Gynecology Clinics of North America, 2021, 48, 705-722.	0.7	2
99	Cotesting in Cervical Cancer Screening. American Journal of Clinical Pathology, 2021, 155, 150-154.	0.4	5
100	Cervical Cancer—A Tragedy We Can Prevent. AMEI S Current Trends in Diagnosis & Treatment, 2021, 4, 00-00.	0.1	0
101	XXXXXXXXX Ãœniversitesi Hastanesi KadÄ±n HastalÄ±klarÄ± ve DoÄŸum PolikliniÄŸi'ne baÅŸvuran hastalarÄ±n servikal smear sonuÃ§larÄ±nÄ±n deÄŸerlendirilmesi. Pamukkale Medical Journal, 0, , .	0.2	0
102	Novel Antigenic Targets of HPV Therapeutic Vaccines. Vaccines, 2021, 9, 1262.	2.1	16
103	The role of endocervicoscopy in women with cervical intraepithelial neoplasia: a systematic review of the literature. Updates in Surgery, 2022, 74, 1239-1245.	0.9	6
104	Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Preventive Medicine, 2022, 154, 106871.	1.6	3
105	Ageâ€specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort of individuals undergoing cervical cancer screening in Mississippi. Cancer Medicine, 2021, 10, 8641-8650.	1.3	9
106	Cervical Screening Practices and Outcomes for Young Women in Response to Changed Guidelines in Calgary, Canada, 2007â€“2016. Journal of Lower Genital Tract Disease, 2021, 25, 1-8.	0.9	2
107	Too soon or too late? Choosing the right screening test intervals. Canadian Family Physician, 2021, 67, 100-106.	0.1	2
109	Screening for cervical cancer: Choices & dilemmas. Indian Journal of Medical Research, 2022, .	0.4	4
110	Early Sexual Health and Reproductive Implications in Pediatric Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2022, 48, 91-112.	0.8	0
111	LASSO and Bioinformatics Analysis in the Identification of Key Genes for Prognostic Genes of Gynecologic Cancer. Journal of Personalized Medicine, 2021, 11, 1177.	1.1	18

#	Article	IF	Citations
112	HPV Testing Behaviors and Willingness to Use HPV Self-sampling at Home Among African American (AA) and Sub-Saharan African Immigrant (SAI) Women. Journal of Racial and Ethnic Health Disparities, 2022, 9, 2485-2494.	1.8	2
113	Emerging Nonpulmonary Complications for Adults With Cystic Fibrosis. Chest, 2022, 161, 1211-1224.	0.4	2
114	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0865.2021.	1.1	3
116	HPV and Pap testing among white, black, and hispanic women: results from a survey study. Discover Social Science and Health, 2021, 1, 1.	0.3	1
117	ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients. PLoS ONE, 2021, 16, e0260915.	1.1	4
118	Reproducibility of Morphologic Parameters of the International Endocervical Adenocarcinoma Criteria and Classification System and Correlation With Clinicopathologic Parameters: A Multi-Institutional Study. International Journal of Gynecological Pathology, 2022, 41, 447-458.	0.9	2
119	Persistent racial disparities in cervical cancer screening with Pap test. Preventive Medicine Reports, 2021, 24, 101652.	0.8	15
120	Coâ€testing in cervical screening among 40â€•to 42â€yearâ€old women is unreasonable. Acta Obstetricia Et Gynecologica Scandinavica, 2022, 101, 374-378.	1.3	5
121	Comparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis. Scientific Reports, 2022, 12, 94.	1.6	12
122	HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m⁶A-MYC expression. International Journal of Biological Sciences, 2022, 18, 507-521.	2.6	42
123	Deep learning based cervical screening by the cross-modal integration of colposcopy, cytology, and HPV test. International Journal of Medical Informatics, 2022, 159, 104675.	1.6	17
124	Cancer statistics, 2022. Ca-A Cancer Journal for Clinicians, 2022, 72, 7-33.	157.7	10,001
125	A Case Report of Advanced Cervical Cancer in a Patient Non-compliant With Age-Appropriate Screening. Cureus, 2022, 14, e21744.	0.2	0
126	The Application of Artificial Intelligence-Assisted Colposcopy in a Tertiary Care Hospital within a Cervical Pathology Diagnostic Unit. Diagnostics, 2022, 12, 106.	1.3	7
127	Awareness and Support of Clinician- and Patient-Collected Human Papillomavirus Testing for Cervical Cancer Screening Among Primary Care Clinicians. Women S Health Reports, 2022, 3, 10-19.	0.4	1
128	Is cervical cancer screening with high-risk human papillomavirus testing superior (or at least as) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Publish Ahead of Print, .	0.0	0
129	Management of Early-Stage Cervical Cancer: A Literature Review. Cancers, 2022, 14, 575.	1.7	34
130	A Comparative Study on the Accuracy and Efficacy Between Dalton and CINtecÂ® PLUS p16/Ki-67 Dual Stain in Triaging HPV-Positive Women. Frontiers in Oncology, 2021, 11, 815213.	1.3	6

#	Article	IF	Citations
131	HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis. Journal of Gynecologic Oncology, 2022, 33, .	1.0	3
132	Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States. Gynecologic Oncology, 2022, 165, 67-74.	0.6	8
133	Sensitivity of AI-Assisted Diagnosis of Cervical ThinPrep Cytological Squamous Lesions Improved by Additional Patient Background Information. SSRN Electronic Journal, 0, , .	0.4	0
134	Cancer statistics for African American/Black People 2022. Ca-A Cancer Journal for Clinicians, 2022, 72, 202-229.	157.7	230
135	When and How Would You Screen This Patient for Cervical Cancer?. Annals of Internal Medicine, 2022, 175, 267-275.	2.0	0
136	Clinical performance of the BD Onclarity extended genotyping assay for the management of women positive for human papillomavirus in cervical cancer screening. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.1082.2021.	1.1	4
137	Knowledge, Attitude, and Practice Toward Cervical Cancer Screening and Associated Factors Among College and University Female Students in Dire Dawa City, Eastern Ethiopia. Cancer Informatics, 2022, 21, 117693512210848.	0.9	3
138	Health Economics Research in Cancer Screening: Research Opportunities, Challenges, and Future Directions. Journal of the National Cancer Institute Monographs, 2022, 2022, 42-50.	0.9	7
139	Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data. Microbiology Spectrum, 2022, 10, e0157021.	1.2	2
140	Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay. Microbiology Spectrum, 2022, 10, e0148021.	1.2	9
141	Explaining Correlates of Cervical Cancer Screening among Minority Women in the United States. Pharmacy (Basel, Switzerland), 2022, 10, 30.	0.6	8
142	How Can We Pursue Equity in Cervical Cancer Prevention With Existing HPV Genotype Differences?. Journal of the National Cancer Institute, 2022, 114, 787-789.	3.0	2
143	Current Management of Locally Advanced and Metastatic Cervical Cancer in the United States. JCO Oncology Practice, 2022, 18, 417-422.	1.4	9
144	US Cancer Screening Recommendations: Developments and the Impact of COVID-19. Medical Sciences (Basel, Switzerland), 2022, 10, 16.	1.3	12
145	Womenâ€™s perception of cervical cancer pap smear screening. Nursing Open, 2022, 9, 1715-1722.	1.1	4
146	Cliniciansâ€™ perceptions of barriers to cervical cancer screening for women living with behavioral health conditions: a focus group study. BMC Cancer, 2022, 22, 252.	1.1	3
147	Artificial Intelligence in Cervical Cancer Screening and Diagnosis. Frontiers in Oncology, 2022, 12, 851367.	1.3	33
148	Early Cervical Lesions Affecting Ovarian Reserve and Reproductive Outcomes of Females in Assisted Reproductive Cycles. Frontiers in Oncology, 2022, 12, 761219.	1.3	3

#	Article	IF	Citations
149	Role of Artificial Intelligence Interpretation of Colposcopic Images in Cervical Cancer Screening. Healthcare (Switzerland), 2022, 10, 468.	1.0	6
150	Human Papillomavirus Infection: Knowledge, Risk Perceptions and Behaviors among SMW and AFAB. Diagnostics, 2022, 12, 843.	1.3	3
151	Should screening for cervical cancer go to primary human papillomavirus testing and eliminate cytology?. Modern Pathology, 2022, 35, 858-864.	2.9	11
152	A Six-Year Gynecological Follow-Up of Immunosuppressed Women with a High-Risk Human Papillomavirus Infection. International Journal of Environmental Research and Public Health, 2022, 19, 3531.	1.2	4
154	Implications for health system resilience: Quantifying the impact of the COVID-19-related stay at home orders on cancer screenings and diagnoses in southeastern North Carolina, USA. Preventive Medicine, 2022, 158, 107010.	1.6	6
155	Human papillomavirus selfâ€sampling: A tool in cancer prevention and sexual health promotion. Sociology of Health and Illness, 2022, 44, 218-235.	1.1	1
156	Patterns of cervical cancer screening among Medicaid beneficiaries. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, , .	1.1	1
157	Gaps and Opportunities to Improve Prevention of Human Papillomavirus-Related Cancers. Journal of Women's Health, 2021, 30, 1667-1672.	1.5	3
158	Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study. International Journal of Cancer, 2022, 150, 1412-1421.	2.3	3
159	OUP accepted manuscript. American Journal of Clinical Pathology, 2022, , .	0.4	0
160	Comparative predictors for cervical cancer screening in Southeast Michigan for Middle Eastern-North African (MENA), White and African American/black women. Preventive Medicine, 2022, , 107054.	1.6	5
161	Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesion cytology, and its immediate risk for high-grade cervical lesion or cancer: a single-center, cross-sectional study. Obstetrics and Gynecology Science, 2022, 65, 335-345.	0.6	1
162	Disparities in the increases of cervical cancer incidence rates: observations from a city-wide population-based study. BMC Cancer, 2022, 22, 419.	1.1	2
163	Cervical Cancer Screening with HPV Testing: Updates on the Recommendation. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 264-271.	0.3	4
164	Computable Guidelines and Clinical Decision Support for Cervical Cancer Screening and Management to Improve Outcomes and Health Equity. Journal of Women's Health, 2022, 31, 462-468.	1.5	14
165	Responding to Pandemic-Associated Changes in Cancer Prevention and Screening. Oncology Nursing Forum, 2022, 49, 189-190.	0.5	0
166	Too soon or too late?. Canadian Family Physician, 2021, 67, 100-106.	0.1	8
167	Trop tÃ´t ou trop tard?. Canadian Family Physician, 2021, 67, e48-e55.	0.1	2

#	Article	IF	Citations
168	Plasma antioxidant capacity in cervical cancer patients. Anais Da Academia Brasileira De Ciencias, 2022, 94, e20201733.	0.3	0
170	A mathematical model of cervical cancer using causal analysis. AIP Conference Proceedings, 2022, , .	0.3	0
172	p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening. Anticancer Research, 2022, 42, 2599-2606.	0.5	3
173	Insights on Proteomics-Driven Body Fluid-Based Biomarkers of Cervical Cancer. Proteomes, 2022, 10, 13.	1.7	1
174	Human papillomavirus anogenital screening in solid organ transplant recipients: a narrative review. Archives of Gynecology and Obstetrics, 2023, 307, 1277-1283.	0.8	2
175	Navigating Financial Barriers to Papanicolaou Tests and Mammograms for Young Adult Women Residing in Rural and Border Areas of Texas. Journal of Adolescent and Young Adult Oncology, 2022, , .	0.7	0
176	In vivo microscopy as an adjunctive tool to guide detection, diagnosis, and treatment. Journal of Biomedical Optics, 2022, 27, .	1.4	10
177	Shifting from cytology to HPV testing for cervical cancer screening in Canada. Cmaj, 2022, 194, E613-E615.	0.9	6
178	Cervical cancer screening guidelines and screening practices in 11 countries: A systematic literature review. Preventive Medicine Reports, 2022, 28, 101813.	0.8	19
179	The Well-Woman Visit. Advances in Family Practice Nursing, 2022, 4, 91-115.	0.1	0
180	Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas, 2022, 163, 1-14.	1.0	33
181	Cancer Groundshot: Building a Robust Cancer Control Platform in Addition To Launching the Cancer Moonshot. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 100-115.	1.8	3
183	Ensuring a Successful Transition From Cytology to Human Papillomavirusâ€“Based Primary Cervical Cancer Screening in Canada by Investigating the Psychosocial Correlates of Womenâ€™s Intentions: Protocol for an Observational Study. JMIR Research Protocols, 2022, 11, e38917.	0.5	6
184	The Effect of Surgeon Volume on the Outcome of Laser Vaporization: A Single-Center Retrospective Study. Current Oncology, 2022, 29, 3770-3779.	0.9	0
185	Cervical Cancer Elimination Is Dependent on Women's Self-Tests for Primary Human Papillomavirus Testing Triaged by Methylation Status. Journal of Clinical Oncology, 0, , .	0.8	4
186	Polygenic risk scores to stratify cancer screening should predict mortality not incidence. Npj Precision Oncology, 2022, 6, .	2.3	5
187	Implementation of HPV Tests in Latin America: What We Learned; What Should We Have Learned, and What Can We Do Better?. Cancers, 2022, 14, 2612.	1.7	5
188	Pricing of HPV tests in Italian tender-based settings. Journal of Medical Economics, 2022, 25, 762-768.	1.0	1

#	Article	IF	Citations
189	Prevalence of Human Papillomavirus Among Chinese Han and Mongols Minority Women in Inner Mongolia, China: Reflected by Self-Collected Samples in CHIMUST. Frontiers in Public Health, 2022, 10, .	1.3	4
190	Performance of cervical screening a decade following HPV vaccination: The Costa Rica Vaccine Trial. Journal of the National Cancer Institute, 0, , .	3.0	1
191	Perceived effectiveness of cancer screening among family medicine and internal medicine physicians in the United States. Preventive Medicine Reports, 2022, 28, 101842.	0.8	0
192	Possible different genotypes for human papillomavirus vaccination in lower middle-income countries towards cervical cancer elimination in 2030: a cross-sectional study. Clinical and Experimental Vaccine Research, 2022, 11, 141.	1.1	0
194	An Expanded Primary Careâ€“Based Womenâ€™s Health Clinic to Improve Resident Education and Patient Care in Resident Continuity Clinic. Journal of General Internal Medicine, 2022, 37, 2314-2317.	1.3	4
195	Current Status of Human Papillomavirus Infection and Cervical Cancer in the Philippines. Frontiers in Medicine, 0, 9, .	1.2	8
196	Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions. British Journal of Cancer, 2022, 127, 1403-1410.	2.9	13
197	Temporal Trends in Cervical Cancer Screening Practices and Associated Downstream Abnormalities and Procedures Among Women With Insurance in the United States. Obstetrics and Gynecology, 2022, 140, 55-64.	1.2	0
198	Trends in the Utilization of Human Papillomavirus Vaccines and the Incidence of Malignant Cervical Cancer in Women and Teenagers: A Secondary Analysis. Healthcare (Switzerland), 2022, 10, 1211.	1.0	1
200	US women screen at low rates for both cervical and colorectal cancers than a single cancer: a cross-sectional population-based observational study. ELife, 0, 11, .	2.8	3
201	Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: A systematic review and meta-analysis. Gynecologic Oncology, 2022, 166, 358-368.	0.6	7
202	Sustainable Green Synthesis of Yttrium Oxide (Y2O3) Nanoparticles Using Lantana camara Leaf Extracts: Physicochemical Characterization, Photocatalytic Degradation, Antibacterial, and Anticancer Potency. Nanomaterials, 2022, 12, 2393.	1.9	18
203	Pre-Procedural Anxiety and Associated Factors Among Women Seeking for Cervical Cancer Screening Services in Shenzhen, China: Does Past Screening Experience Matter?. Frontiers in Oncology, 0, 12, .	1.3	2
204	Can the combination of DWI and T2WI radiomics improve the diagnostic efficiency of cervical squamous cell carcinoma?. Magnetic Resonance Imaging, 2022, 92, 197-202.	1.0	3
206	Topical 5-aminolevulinic acid photodynamic therapy for cervical high-grade squamous intraepithelial lesions. Photodiagnosis and Photodynamic Therapy, 2022, 39, 103037.	1.3	4
207	Association between Cervical Microbiota and HPV: Could This Be the Key to Complete Cervical Cancer Eradication?. Biology, 2022, 11, 1114.	1.3	34
208	The necessity of continuing cervical cancer screening of elderly Korean women aged 65â€‰years or older. Diagnostic Cytopathology, 2022, 50, 482-490.	0.5	1
209	Transition de la cytologie Ã la dÃ©tection du VPH pour le dÃ©pistage du cancer du col de lâ€™utÃ©rus au Canada. Cmaj, 2022, 194, E1012-E1014.	0.9	0

#	Article	IF	Citations
210	Correlative study between apparent diffusion coefficient value and grading of cervical cancer. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	1
211	Determinants of Cervical Cancer Screening Patterns Among Women With Systemic Lupus Erythematosus. Journal of Rheumatology, 0, , jrheum.220105.	1.0	3
212	Womenâ€™s attitudes towards a human papillomavirus-based cervical cancer screening strategy: a systematic review. BMJ Sexual and Reproductive Health, 2022, 48, 295-306.	0.9	5
213	Changing Preferences for a Cervical Cancer Screening Strategy: Moving Away from Annual Testing. Women S Health Reports, 2022, 3, 709-717.	0.4	0
214	Singleâ€cell RNAâ€sequencing dissects cellular heterogeneity and identifies two tumorâ€suppressing immune cell subclusters in HPVâ€related cervical adenosquamous carcinoma. Journal of Medical Virology, 2022, 94, 6047-6059.	2.5	14
216	Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	4
217	Sociodemographic factors associated with HPV awareness/knowledge and cervical cancer screening behaviors among caregivers in the U.S. BMC Women's Health, 2022, 22, .	0.8	7
218	Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis. Experimental Cell Research, 2022, 418, 113294.	1.2	38
219	Clinical Performance of the RealTi m e High Risk HPV Assay on Self-Collected Vaginal Samples within the VALHUDES Framework. Microbiology Spectrum, 2022, 10, .	1.2	8
220	An overview of HPV: Causes, symptoms, and clinical manifestations. , 2022, , 1-19.		0
221	Current diagnostic tools for HPV. , 2022, , 99-118.		0
222	Essential laboratory tests for medical education. Academic Pathology, 2022, 9, 100046.	0.7	3
223	Sensitivity of AI-Assisted Diagnosis of Cervical Thinprep Cytological Squamous Lesions Improved by Additional Patient Background Information. SSRN Electronic Journal, 0, , .	0.4	0
224	Communications Is Time for Care: An Italian Monocentric Survey on Human Papillomavirus (HPV) Risk Information as Part of Cervical Cancer Screening. Journal of Personalized Medicine, 2022, 12, 1387.	1.1	9
225	AHNAK2 is a biomarker and a potential therapeutic target of adenocarcinomas. Acta Biochimica Et Biophysica Sinica, 2022, 54, 1708-1719.	0.9	3
226	Detection of Pancreatic Cancer miRNA with Biocompatible Nitrogen-Doped Graphene Quantum Dots. Materials, 2022, 15, 5760.	1.3	14
227	An Overview of HPV Screening Tests to Improve Access to Cervical Cancer Screening Amongst Underserved Populations: From Development to Implementation. Risk Management and Healthcare Policy, 0, Volume 15, 1823-1830.	1.2	5
228	Cervical cancer screening and outcomes for women under 25 years of age in Belgium: a 10-year nationwide study. European Journal of Cancer Prevention, 2023, 32, 163-170.	0.6	2

#	Article	IF	Citations
229	Clinical characteristics and a 2-year follow-up of unsatisfactory conventional Pap smears: a retrospective caseâ€“control study. Scientific Reports, 2022, 12, .	1.6	1
230	Disparities in Diagnosis and Treatment of Cervical Adenocarcinoma Compared With Squamous Cell Carcinoma: An Analysis of the National Cancer Database, 2004â€“2017. Journal of Lower Genital Tract Disease, 2023, 27, 29-34.	0.9	6
231	Secondary Prevention of Cervical Cancer: ASCO Resourceâ€“Stratified Guideline Update. JCO Global Oncology, 2022, , .	0.8	8
232	Evaluation of Harms Reporting in U.S. Cancer Screening Guidelines. Annals of Internal Medicine, 2022, 175, 1582-1590.	2.0	10
233	Underscreening, overscreening, and guideline-adherent cervical cancer screening in a national cohort. Gynecologic Oncology, 2022, 167, 181-188.	0.6	6
234	Multicontrast Pocket Colposcopy Cervical Cancer Diagnostic Algorithm for Referral Populations. BME Frontiers, 2022, 2022, .	2.2	6
235	Piloting a systems level intervention to improve cervical cancer screening, treatment and follow up in Kenya. Frontiers in Medicine, 0, 9, .	1.2	1
236	Nomogram models for the prognosis of cervical cancer: A SEER-based study. Frontiers in Oncology, 0, 12, .	1.3	8
237	Identification of Oxidative Stress-Associated Molecular Subtypes and Signature for Predicting Survival Outcome of Cervical Squamous Cell Carcinoma. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-42.	1.9	2
238	Cervical cancer screening: Past, present and outlook. , 2022, 96, 333-341.		0
239	Primary screening of cervical cancer by Pap smear in women of reproductive age group. Journal of Family Medicine and Primary Care, 2022, 11, 5327.	0.3	1
240	HPV test as a primary screening test in the prevention of cervical carcinoma in the Republic of Croatia. , 2022, 96, 323-332.		0
241	Review of HPV testing for primary cervical cancer screening. , 2022, 96, 279-301.		0
242	Risk factors for cervical cytological abnormalities among women infected with non-16/18 high-risk human papillomavirus: a cross-sectional study (Preprint). JMIR Public Health and Surveillance, 0, , .	1.2	0
243	Awareness, Knowledge, Perceptions, and Attitudes towards Familial and Inherited Cancer. Medicina (Lithuania), 2022, 58, 1400.	0.8	1
244	Low Level FLT3LG is a Novel Poor Prognostic Biomarker for Cervical Cancer with Immune Infiltration. Journal of Inflammation Research, 0, Volume 15, 5889-5904.	1.6	3
245	Current gaps and opportunities in screening, prevention, and treatment of cervical cancer. Cancer, 2022, 128, 4063-4073.	2.0	5
246	Dosimetric and feasibility evaluation of a CBCTâ€based daily adaptive radiotherapy protocol for locally advanced cervical cancer. Journal of Applied Clinical Medical Physics, 2023, 24, .	0.8	10

#	Article	IF	Citations
247	The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer. Genome Medicine, 2022, 14, .	3.6	6
248	Comparison of primary cytology, primary HPV testing and co-testing as cervical cancer screening for Chinese women: a population-based screening cohort. BMJ Open, 2022, 12, e063622.	0.8	2
249	Distribution of microbiota in cervical preneoplasia of racially disparate populations. BMC Cancer, 2022, 22, .	1.1	2
251	Rising to the De-escalation Challenge: Multilevel Change Needed to Align Clinical Practice with Cancer Screening Guidelines. Medical Decision Making, 2022, 42, 1045-1047.	1.2	0
252	Factors associated with timely colposcopy following an abnormal cervical cancer test result. Preventive Medicine, 2022, 164, 107307.	1.6	6
253	A study protocol for a cluster randomized pragmatic trial for comparing strategies for implementing primary HPV testing for routine cervical cancer screening in a large health care system. Contemporary Clinical Trials, 2023, 124, 106994.	0.8	0
254	High-Risk HPV Genotype Distribution According to Cervical Cytology and Age. Open Forum Infectious Diseases, 0, , .	0.4	0
255	Design of a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake in a U.S. healthcare system: The STEP trial. Contemporary Clinical Trials, 2022, 122, 106960.	0.8	1
256	Knowledge, attitudes and practices toward cervical cancer and screening among sexually active Saudi females visiting a primary care center in Saudi Arabia. Journal of Family Medicine and Primary Care, 2022, 11, 6121.	0.3	1
257	Patient delay and related influencing factors in Chinese women under 35 years diagnosed with cervical cancer: A cross-sectional study. Asia-Pacific Journal of Oncology Nursing, 2022, , 100165.	0.7	0
258	Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening. Frontiers in Public Health, 0, 10, .	1.3	0
259	The polymethoxylated flavone hexamethylquercetagetin suppresses NF-Î²B signaling and inhibits cell survival in cervical carcinoma. Growth Factors, 0, , 1-7.	0.5	0
260	Interest in Continued Use After Participation in a Study of Over-the-Counter Progestin-Only Pills in the United States. Women S Health Reports, 2022, 3, 904-914.	0.4	2
262	Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting. Experimental Hematology and Oncology, 2022, 11, .	2.0	5
263	Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study. BMC Medicine, 2022, 20, .	2.3	0
264	Human Papillomavirus. , 2023, , 1119-1123.e1.		0
265	Equity enhancing policies that increase access and affordability of cervical cancer screening in the United States: A Preventive Medicine Golden Jubilee Commentary. Preventive Medicine, 2023, 166, 107383.	1.6	0
266	Clinician practices, knowledge, and attitudes regarding primary human papillomavirus testing for cervical cancer screening: A mixed-methods study in Indiana. Preventive Medicine Reports, 2023, 31, 102070.	0.8	3

#	Article	IF	Citations
268	Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit. JAMA Network Open, 2022, 5, e2244343.	2.8	2
269	Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genomeâ€“Positive C3 Cancers in Mice. Cancer Immunology Research, 2023, 11, 261-275.	1.6	5
270	Potential effects of age-based changes in screening guidelines on the identification of women at risk for developing cervical cancer. Cancer Prevention Research, 0, , .	0.7	0
271	High-Risk Human Papillomavirus Detection via CobasÂ® 4800 and REBA HPV-IDÂ® Assays. Viruses, 2022, 14, 2713.	1.5	0
272	Cancer prevention in females with and without obesity: Does perceived and internalised weight bias determine cancer prevention behaviour?. BMC Women's Health, 2022, 22, .	0.8	1
273	A Rare Case of Aggressive Atypical Cervical Cancer With Multi-Organ Involvement. Cureus, 2022, , .	0.2	1
274	Health care personnelâ€™s perspectives on human papillomavirus (HPV) self-sampling for cervical cancer screening: a pre-implementation, qualitative study. Implementation Science Communications, 2022, 3, .	0.8	0
275	Cervical Cancer Screening. Medical Clinics of North America, 2023, 107, 259-269.	1.1	6
276	Genital HPV Prevalence, Follow-Up and Persistence in Males and HPV Concordance Between Heterosexual Couples in Wenzhou, China. Infection and Drug Resistance, 0, Volume 15, 7053-7066.	1.1	0
277	Exploring engagement in cervical cancer prevention services among Haitian women in Haiti and in the United States: a scoping review. Journal of Psychosocial Oncology, 0, , 1-20.	0.6	1
278	The Global, Regional, and National Burdens of Cervical Cancer Attributable to Smoking From 1990 to 2019: Population-Based Study. JMIR Public Health and Surveillance, 2022, 8, e40657.	1.2	5
279	Highâ€risk <scp>HPV</scp> testing vs liquidâ€based cytology for cervical cancer screening among 25â€•to 30â€yearâ€old women: A historical cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2023, 102, 226-233.	1.3	3
280	Frequency of cervical premalignant lesions in the gynecologic patients of a tertiary hospital in Mogadishu, Somalia. BMC Women's Health, 2022, 22, .	0.8	0
281	Impact of highâ€risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Realâ€world data from regional cervical cancer screening program. Journal of Medical Virology, 2023, 95, .	2.5	3
282	Paiteling induces apoptosis of cervical cancer cells by down-regulation of the E6/E7-Pi3k/Akt pathway: A network pharmacology. Journal of Ethnopharmacology, 2023, 305, 116062.	2.0	3
283	Human Papillomavirus: Challenges and Opportunities for the Control of Cervical Cancer. Archives of Medical Research, 2022, 53, 753-769.	1.5	10
284	Prescription of hormone replacement therapy among cervical cancer patients with treatment-induced premature menopause. International Journal of Gynecological Cancer, 0, , ijgc-2022-003861.	1.2	0
285	Epidemiological/Disease and Economic Burdens of Cervical Cancer in 2010â€“2014: Are Younger Women at Risk?. Healthcare (Switzerland), 2023, 11, 144.	1.0	2

#	Article	IF	Citations
286	Cervical Cancer Stage at Diagnosis and Survival among Women â‰¥65 Years in California. Cancer Epidemiology Biomarkers and Prevention, 2023, 32, 91-97.	1.1	8
287	Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer. Journal of Radiation Research, 0, , .	0.8	0
288	Xâ€Rayâ€Responsive Zeolitic Imidazolate Frameworkâ€Capped Nanotherapeutics for Cervical Cancerâ€Targeting Radiosensitization. Advanced Functional Materials, 2023, 33, .	7.8	11
289	Prevalence of human papillomavirus genotypes and related cervical morphological results in southern Hunan Province of China, 2018â€“2020: Baseline measures at a tertiary institution prior to mass human papillomavirus vaccination. Frontiers in Microbiology, 0, 13, .	1.5	1
290	Significant outcomes associated with high-risk human papillomavirus negative Papanicolaou tests. Journal of the American Society of Cytopathology, 2023, 12, 189-196.	0.2	3
291	Risk stratification for cervical precancer and cancer by DH3â€HPV partial genotyping and cytology in women attending cervical screening: AÂretrospective cohort study. Journal of Medical Virology, 2023, 95, .	2.5	0
292	Translation, Adaptation, and Validation of the Modified Thai Version of Championâ€™s Health Belief Model Scale (MT-CHBMS). Healthcare (Switzerland), 2023, 11, 128.	1.0	2
293	Knowledge, perception, and sources of information towards cervical cancer and utilization of papanicolaou (pap) smear as screening among female in medina, Saudi Arabia. Obstetrics & Gynecology International Journal, 2022, 13, 378-383.	0.0	0
294	Association and Effectiveness of PAX1 Methylation and HPV Viral Load for the Detection of Cervical High-Grade Squamous Intraepithelial Lesion. Pathogens, 2023, 12, 63.	1.2	1
295	Squamous Intraepithelial Lesions of the Uterine Cervix The Long and Winding Road of Our Understanding of Their Morphology, Biology, and the Terminology That Describes Themâ€”From First to LAST. International Journal of Gynecological Pathology, 2023, 42, 109-119.	0.9	0
296	Classification of normal and abnormal overlapped squamous cells in pap smear image. International Journal of Systems Assurance Engineering and Management, 2024, 15, 519-531.	1.5	1
297	Candidate Genes and Pathways in Cervical Cancer: A Systematic Review and Integrated Bioinformatic Analysis. Cancers, 2023, 15, 853.	1.7	1
299	The Rise of Extracellular Vesicles as New Age Biomarkers in Cancer Diagnosis: Promises and Pitfalls. Technology in Cancer Research and Treatment, 2023, 22, 153303382211492.	0.8	6
300	Factors Associated with Unsatisfactory Pap Tests Among Sexually Active Trans Masculine Adults. LGBT Health, 2023, 10, 278-286.	1.8	1
301	Womenâ€™s Health Maintenance Efforts at a Student-Run Free Clinic in South Florida Exceeded National Trends During the COVID-19 Pandemic. Journal of Community Health, 0, , .	1.9	0
302	Cervical cancer screening in Jordan; aÂreview ofÂtheÂpast and an outlook to theÂ future â€“ facts and figures. Przeglad Menopauzalny, 0, , .	0.6	0
303	Management of Intraepithelial Lesions of the Cervix. , 2023, , 1-16.		0
304	Preventative Care in Scleroderma. Rheumatic Disease Clinics of North America, 2023, 49, 411-423.	0.8	0

#	Article	IF	Citations
305	A CAD system for automatic dysplasia grading on H&E cervical whole-slide images. Scientific Reports, 2023, 13, .	1.6	3
306	AACC Guidance Document on Cervical Cancer Detection: Screening, Surveillance, and Diagnosis. journal of applied laboratory medicine, The, 2023, 8, 382-406.	0.6	1
307	Interpretable pap-smear image retrieval for cervical cancer detection with rotation invariance mask generation deep hashing. Computers in Biology and Medicine, 2023, 154, 106574.	3.9	3
308	An insight into clinical and laboratory detections for screening and diagnosis of cervical cancer. Expert Review of Molecular Diagnostics, 2023, 23, 29-40.	1.5	2
309	Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)â€“Study protocol. PLoS ONE, 2023, 18, e0278077.	1.1	0
310	A questionnaire study on disparity of cervical cancer prevention programs in <scp>Asiaâ€Oceania</scp>. Journal of Obstetrics and Gynaecology Research, 2023, 49, 1230-1243.	0.6	2
311	Cervical Cancer: A Review of Epidemiology, Treatments and Anticancer Drugs. Current Cancer Therapy Reviews, 2023, 19, 198-212.	0.2	3
312	Cervical cancer screening: missed opportunities in a one-track model. International Journal of Gynecological Cancer, 2023, 33, 646-646.	1.2	0
313	Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies. Frontiers in Neurology, 0, 14, .	1.1	1
314	Telecytologic diagnosis of cervical smears for triage of self-sampled human papillomavirusâ€“positive women in a resource-limited setting: concept development before implementation. Journal of the American Society of Cytopathology, 2023, 12, 170-180.	0.2	1
315	Harmonizing Qualitative Data Across Multiple Health Systems to Identify Quality Improvement Interventions: A Methodological Framework Using PROSPR II Cervical Research Center Data as Exemplar. International Journal of Qualitative Methods, The, 2023, 22, 160940692311573.	1.3	0
316	Classification and Biomarkers of Lower Female Genital Tract Neoplasia. , 2023, , 19-34.		0
317	A Review of the Scope of Direct-to-Consumer Sexually Transmitted Infection Testing Services Offered on the Internet. Sexually Transmitted Diseases, 2023, 50, 323-328.	0.8	1
319	Independent risk factors for high-risk human papillomavirus infection among rural women in Shanxi Province, China: a population-based, caseâ€“control study. Archives of Gynecology and Obstetrics, 0, , .	0.8	0
320	Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic. Journal of Clinical Oncology, 2023, 41, 4352-4359.	0.8	23
321	The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis. Clinical Therapeutics, 2023, 45, 278-289.	1.1	5
322	Understanding the effect of new U.S. cervical cancer screening guidelines and modalities on patientsâ€™ comprehension and reporting of their cervical cancer screening behavior. Preventive Medicine Reports, 2023, 32, 102169.	0.8	1
323	Barriers driving health care disparities in utilization of age-appropriate screening. Frontiers in Public Health, 0, 11, .	1.3	0

#	Article	IF	Citations
324	PSGL-1 is a novel tumor microenvironment prognostic biomarker with cervical high-grade squamous lesions and more. Frontiers in Oncology, 0, 13, .	1.3	4
325	Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection. PLoS ONE, 2023, 18, e0282853.	1.1	3
326	Latent HPV Infection: Does HPV Last Forever in Some Women?. Journal of Women's Health, 0, , .	1.5	0
327	Pap smear recommendations in older women, does the data support stopping?. Current Opinion in Obstetrics and Gynecology, 2023, 35, 160-163.	0.9	2
328	Economic Evaluation of Mailed Home-Based Human Papillomavirus Self-sampling Kits for Cervical Cancer Screening. JAMA Network Open, 2023, 6, e234052.	2.8	3
329	miRâ€145 inhibits aerobic glycolysis and cell proliferation of cervical cancer by acting on MYC. FASEB Journal, 2023, 37, .	0.2	3
330	Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States. International Journal of Cancer, 0, , .	2.3	1
331	Perspectives of the prevention of cervical cancer in the Republic of Tajikistan. Zdravoohranenie TadÅ¾ikistana, 2023, , 60-66.	0.2	0
332	Lack of awareness of human papillomavirus testing among U.S. women. American Journal of Preventive Medicine, 2023, , .	1.6	0
333	Human Papilloma Virus: An Unraveled Enigma of Universal Burden of Malignancies. Pathogens, 2023, 12, 564.	1.2	4
334	Changes over time in papanicolaou cytology test and HPV test in a large womenâ€™s academic center laboratory. Journal of the American Society of Cytopathology, 2023, 12, 307-313.	0.2	2
335	Improving the Accuracy and Efficiency of Abnormal Cervical Squamous Cell Detection With Cytologist-in-the-Loop Artificial Intelligence. Modern Pathology, 2023, 36, 100186.	2.9	1
336	Exogenous Factors and Cancer. , 2023, , 52-85.		0
337	Highâ€grade squamous intraepithelial lesion cervicovaginal paps with negative highâ€risk <scp>HPV</scp> testing, a prospective study with histological followâ€up. Diagnostic Cytopathology, 0, , .	0.5	0
343	Tumor-Infiltrating Lymphocytes (TILs) and Gynecological Cancers. , 2023, , .		1
348	Carcinogenesis and management of human papillomavirus-associated cervical cancer. International Journal of Clinical Oncology, 2023, 28, 965-974.	1.0	3
404	Preventive Health Visit. , 2023, , 265-279.		0
414	Conventional Cervical Cytology Image Dataset with Cell Outline Annotations. , 2023, , .		0

#	Article	IF	Citations
415	Molecular testing for human papillomaviruses. , 2024, , 79-93.		0
424	Cancer Screening in the Older Adult. , 2023, , 1-25.		0
441	Management of Intraepithelial Lesions of the Cervix. , 2023, , 63-78.		0
464	Cancer Screening in the Older Adult. , 2024, , 801-825.		0
467	Family Medicine. , 2024, , .		0